Recently, lenalidomide, a CRBN/RBX1 inhibitor, has shown protective roles in multiple COVID-19–infected myeloma patients against progression into severe infections [37], which suggests the emergence of this particular platelet subpopulation may drive the disease severity in COVID-19 infection. The gene discussed is RBX1; the disease is plasma cell myeloma.